Literature DB >> 9836546

Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.

G Smits1, E Schaafsma, L Kiemeney, C Caris, F Debruyne, J A Witjes.   

Abstract

OBJECTIVES: To evaluate microstaging by means of quantifying the depth of invasion of the subepithelial connective tissue in pT1 transitional cell carcinoma (TCC) of the bladder for its additional prognostic value with respect to disease recurrence and progression.
METHODS: We reviewed the pathologic findings of a consecutive series of 124 patients with pT1 tumors entered in a prospective randomized multicenter trial comparing mitomycin C and bacillus Calmette-Guérin treatment, with at least 3 years of follow-up and clinical outcome hidden from reviewers. The depth of invasion was established by identifying submucosal tumor invasion up to, in, or beyond the muscularis mucosae or vascular plexus and classified as pT1a, pT1b, or pT1c, respectively. In addition to tumor grade, the presence of carcinoma in situ (CIS) near the primary tumor or in biopsy specimens taken from abnormal looking mucosa was taken into account. The risks of recurrence and progression were calculated using Kaplan-Meier curves and modeled with proportional hazard models.
RESULTS: pT1 subclassification was possible in more than 90% of the specimens. The 3-year risk of recurrence was not different in any of the subgroups. By contrast, the Kaplan-Meier 3-year risk for progression was 6%, 33%, and 55% for pT1a, pT1b (hazard ratio [HR] 5.51), and pT1c (HR 12.35) tumors, respectively (log-rank test P < 0.001). The Kaplan-Meier 3-year risk of progression was 9% versus 39% (HR 5.62) for the absence or presence of CIS in the tumor (P=0.001) and 8% versus 49% (HR 6.72) for CIS in biopsy specimens (P < 0.001). Tumor grade had no statistically significant prognostic value with respect to progression, nor had tumor volume or multifocality. The combination of the parameters (pT1c and CIS) increased the risk of progression by a factor of 27 (P < 0.0001) compared with the absence of pT1c and CIS.
CONCLUSIONS: These data show that the extent of lamina propria invasion (pT1a, pT1b, pT1c) is a clinically relevant prognostic factor for progression of pT1 TCC of the bladder. With the combination of this pT1 subclassification and the presence of CIS subgroups, distinct risks of progression can be identified that may give additional information for follow-up and treatment policies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836546     DOI: 10.1016/s0090-4295(98)00374-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  Consistency of microstaging pT1 bladder transitional cell carcinoma.

Authors:  Lorna Cottrell; Edwin Robert Nairn; Mario Hair
Journal:  J Clin Pathol       Date:  2007-02-23       Impact factor: 3.411

2.  The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy.

Authors:  John P Stein; David F Penson
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

3.  Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.

Authors:  Erfan Amini; Nariman Ahmadi; Thomas G Clifford; Cory M Hugen; Soroush T Bazargani; Jie Cai; Gus Miranda; Andy E Sherrod; Siamak Daneshmand; Hooman Djaladat
Journal:  Int Urol Nephrol       Date:  2019-01-31       Impact factor: 2.370

4.  Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression.

Authors:  Shugo Yajima; Soichiro Yoshida; Taro Takahara; Yuki Arita; Hiroshi Tanaka; Yuma Waseda; Minato Yokoyama; Junichiro Ishioka; Yoh Matsuoka; Kazutaka Saito; Kazunori Kihara; Yasuhisa Fujii
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

5.  The effect of tumor invasion patterns on pathologic stage of bladder urothelial carcinomas.

Authors:  Sema Bircan; Ozden Candir; Nilgun Kapucuoglu
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

Review 6.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

7.  Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.

Authors:  H Barton Grossman; Michael A O'Donnell; Michael S Cookson; Richard E Greenberg; Thomas E Keane
Journal:  Rev Urol       Date:  2008

8.  Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.

Authors:  M G W Bol; J P A Baak; B van Diermen; S Buhr-Wildhagen; E A M Janssen; K H Kjellevold; A J Kruse; O Mestad; P Øgreid
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

9.  Vascular plexus is a differentation criterion for muscularis mucosa from muscularis propria in small biopsies and transurethral resection materials of urinary bladder?

Authors:  Abdullah Aydin; Ramazan Uçak; Metin Karakök; Muhammed Emin Güldür; Nazim Emrah Koçer
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

10.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history.

Authors:  Erik Pasin; David Y Josephson; Anirban P Mitra; Richard J Cote; John P Stein
Journal:  Rev Urol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.